Statins and diabetes mellitus: price of collaboration
| Autor: | Svetlana Semenovna Kukharenko, M N Yadrikhinskaya, Andrey Alexeevich Aleksandrov, Olga Alexandrovna Shatskaya |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_specialty
RC620-627 Endocrinology Diabetes and Metabolism glycemic disorders cardiovascular complications law.invention statins Endocrinology Randomized controlled trial law Internal medicine Diabetes mellitus Internal Medicine Medicine In patient Nutritional diseases. Deficiency diseases Glycemic Secondary prevention business.industry Incidence (epidemiology) dyslipidemia nutritional and metabolic diseases medicine.disease diabetes mellitus Life expectancy Physical therapy business Dyslipidemia |
| Zdroj: | Сахарный диабет, Vol 15, Iss 2, Pp 70-76 (2012) |
| ISSN: | 2072-0378 2072-0351 |
| Popis: | It is now well established that clinical use of statins for primary and secondary prevention of cardiovascular complications in patientswith diabetes mellitus (DM) increases life expectancy. At the same time, meta-analysis of major randomized trials shows statins to increaseglycemic levels and incidence of diabetic symptoms, especially in patients at risk for developing glycemic disorders. However,comparison of positive and negative effects of statins suggests prevalence of clinically beneficial factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|